Merck Sharp & Dohme Llc

This early-stage study is testing two new vaccine candidates (V350A and V350B) designed to prevent diseases caused by Epstein-Barr virus (EBV), which is linked to mononucleosis, multiple sclerosis, and certain cancers. The trial will enroll 200 healthy adults to primarily assess …

This study is testing an experimental vaccine, called V181, to see if it can safely prevent dengue fever in healthy children and teenagers. It will involve about 12,000 participants aged 2 to 17 years old. Researchers will compare the vaccine to a placebo (a shot with no active m…

This early-stage study is testing the safety and immune response of a new vaccine called V118E, designed to protect against illnesses caused by pneumonia bacteria. Researchers will enroll 126 healthy adults to monitor for side effects like injection-site reactions, fever, or fati…

This study is testing a new vaccine called V118C designed to protect children from pneumococcal infections, which can cause pneumonia and other serious illnesses. Researchers will enroll about 210 infants and toddlers to compare the safety and immune response of V118C against an …

This large Phase 3 trial is testing whether two new drug combinations work better than current standard treatments for advanced HR+/HER2- breast cancer. The study will enroll 1,200 participants whose cancer has progressed despite previous hormone-based therapies. Researchers will…

This study is testing several new investigational drugs, given alone or in combination with an existing immunotherapy drug (pembrolizumab), for people with an aggressive form of lung cancer called extensive-stage small cell lung cancer. The cancer in these participants has contin…

This is an early-stage study testing a new medication called MK-1045 in people with lupus and rheumatoid arthritis. The main goal is to check the safety and side effects of different doses and see how the body processes the drug. Researchers will also measure if the treatment red…

This study aims to learn about the long-term safety of a drug called sotatercept for people with pulmonary arterial hypertension (PAH). It is a follow-up study for people who have already taken sotatercept in previous trials. The main goal is to see how well people tolerate the d…

This study is comparing a newer immunotherapy drug called pembrolizumab against standard chemotherapy for Chinese patients with advanced colorectal cancer that has spread. The trial aims to see if the immunotherapy can better control the cancer's growth and help patients live lon…

This study tests whether a new drug combination works better than the current standard treatment for an aggressive type of blood cancer called GCB DLBCL. Researchers will compare zilovertamab vedotin plus R-CHP against polatuzumab vedotin plus R-CHP in nearly 600 people who haven…

This study is testing whether a new investigational drug, enlicitide, works better when given alongside a standard cholesterol medication called rosuvastatin. It will involve about 975 adults with high cholesterol (hyperlipidemia). The main goal is to see if the combination lower…

This study is testing whether adding a new drug called patritumab deruxtecan to standard chemotherapy and immunotherapy before surgery works better for certain aggressive breast cancers. Researchers want to see if this combination helps eliminate more cancer cells before surgery …

This study is testing new drug combinations for people with advanced stomach or esophageal cancer that has continued to grow after their first treatment. It will compare the safety and effectiveness of two experimental drug combinations against a standard treatment. The goal is t…

This study follows patients who are already taking the cancer drug belzutifan in earlier trials. Researchers want to understand the long-term survival benefits and safety of this medication for people with advanced solid tumors or tumors related to Von Hippel-Lindau disease. Only…

This is an early safety study for a new HIV medication called MK-4646. It will test the drug in 28 people who have HIV but have not yet started standard treatment. The main goals are to see if the pill is safe and if it can lower the amount of HIV virus in the blood.

This study is testing whether adding a new drug called belzutifan to standard hormone therapy (fulvestrant) works better than current standard treatments for people with advanced breast cancer. It will involve about 120 adults whose cancer has grown despite previous hormone-based…

This study is testing whether adding a new targeted drug (MK-1084) to an existing immunotherapy helps prevent lung cancer from returning after surgery. It's for people with a specific genetic mutation (KRAS G12C) whose cancer was removed but has a high risk of coming back. The ma…

This study allows patients who are already taking the experimental drug bomedemstat for certain rare blood cancers to continue treatment in a long-term follow-up study. The main goal is to collect more information about the drug's safety and how well it continues to work over a l…

This study is testing if a new combination of two HIV drugs, taken just once a week, works as well and is as safe as the current standard daily treatment. It will involve about 570 adults who have just been diagnosed with HIV-1 and have not yet started any medication. The main go…

This study is testing new, targeted cancer drugs called antibody-drug conjugates (ADCs) for people with advanced squamous non-small cell lung cancer (NSCLC) that has continued to grow despite standard immunotherapy and chemotherapy. The main goals are to see if these new treatmen…

This study is testing an experimental drug called patritumab deruxtecan for people with advanced HER2-positive breast cancer that has spread or cannot be surgically removed. Researchers want to find the safest dose and see if the drug can shrink tumors in 81 participants who have…

This study is testing whether a new drug combination works better than the current standard treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to prior therapy. Researchers will compare the safety and effec…

This study is testing whether a combination of two drugs (belzutifan and zanzalintinib) helps people with advanced kidney cancer live longer and keeps their cancer from getting worse, compared to the standard treatment (cabozantinib). The trial will enroll about 900 participants …

This study is testing whether a new drug called sacituzumab tirumotecan, given alone or with pembrolizumab, works better than standard chemotherapy for people with advanced triple-negative breast cancer. It will involve about 1,000 participants who haven't had prior treatment for…

This study is testing a new targeted cancer drug called HER3-DXd in children with hepatoblastoma (a liver cancer) or rhabdomyosarcoma (a muscle cancer) that has returned after treatment or hasn't responded to other therapies. The research aims to find a safe dose for children and…

This early-stage study is testing a new experimental drug called MK-0472 in people with advanced or metastatic solid tumors. Researchers want to find the safest dose and see how well the drug works when given alone or combined with other cancer therapies. The study will enroll ab…

This early-stage study aims to check the safety and side effects of a new experimental drug called MK-1403 in people with type 2 diabetes. It will involve 52 participants and will measure how the drug moves through the body and its effect on a blood marker linked to inflammation …

This study is testing an experimental drug called patritumab deruxtecan for people with advanced gastrointestinal cancers that have spread. The main goals are to find a safe dose and to see if the treatment causes tumors to shrink or go away. It is for adults with specific cancer…

This large study is testing whether adding a new drug called zilovertamab vedotin to standard lymphoma treatment helps people live longer without their cancer growing or spreading. Over 1,000 adults with untreated diffuse large B-cell lymphoma will receive either the new combinat…

This study is testing two new targeted cancer drugs against standard chemotherapy for people with advanced lung cancer that has spread and stopped responding to prior immunotherapy and chemotherapy. The goal is to see if these new drugs are safer and more effective at shrinking t…

This study is comparing a new targeted drug called MK-2870 (sacituzumab tirumotecan) against standard chemotherapy for people with advanced non-small cell lung cancer that has specific genetic changes and has stopped responding to previous treatments. The trial will enroll 556 pa…

This study is testing an experimental drug called MK-1084, given alone or with an existing drug (cetuximab), for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to see if the treatment shrinks tumors and how safe it is fo…

This study is testing whether a new drug called opevesostat works better than two standard treatments (abiraterone or enzalutamide) for men with advanced prostate cancer that has spread and stopped responding to prior hormone therapy. The main goal is to see if opevesostat can ke…

This study is testing whether new maintenance drugs can help women with recurrent ovarian cancer live longer without their cancer getting worse. After completing standard chemotherapy, participants will receive either the new drug combinations or standard care to see which works …

This study is testing whether adding a new personalized cancer vaccine (V940) to standard immunotherapy (pembrolizumab) works better for advanced melanoma that has spread. The goal is to see if this combination helps patients live longer without their cancer getting worse compare…

This study is tracking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in patients who were already receiving it in previous Merck trials. It will follow 3,500 people with various solid tumors or blood cancers to see how they do over an extended…

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goals are to check if the drug is safe and if people can tolerate it, while also seeing if it helps shrink tumors or slow cancer growth…

This study is testing a new targeted cancer drug called raludotatug deruxtecan in women whose ovarian cancer has returned after previous chemotherapy. The drug works like a 'smart bomb' that attaches to cancer cells and delivers treatment directly to them. Researchers want to fin…

This study is testing a new two-drug combination for people newly diagnosed with extensive-stage small cell lung cancer, a fast-spreading type of lung cancer. Researchers want to see if the drugs gocatamig and I-DXd, given together and sometimes with standard chemotherapy, are sa…

This study aims to find the right dose and check the safety of a daily HIV medication combination for young children. It will include up to 84 children under 12 years old who have HIV-1 and weigh less than 45 kg. The main goal is to see how the drug moves through their bodies and…

This is the first human study of an experimental drug called MK-8294, designed to target certain advanced solid tumors. The main goal is to find the highest dose that is safe and tolerable for patients. It is enrolling about 67 adults with specific advanced cancers who have no ot…

This large study is testing various new drug combinations, including pembrolizumab with or without chemotherapy, for people with advanced non-small cell lung cancer. It will enroll over 1,000 participants across multiple smaller substudies, each focusing on different patient grou…

This study is testing if adding a new targeted drug, sacituzumab tirumotecan, to an existing immunotherapy (pembrolizumab) works better than the immunotherapy alone to control advanced endometrial cancer. It is for over 1,100 people whose cancer has spread or returned after surge…

This study is testing whether an experimental drug called MK-2214 can slow the progression of early Alzheimer's disease. Researchers will enroll 340 people with mild memory problems or early dementia to receive either the drug or a placebo. The main goal is to see if MK-2214 redu…

This study is testing new drug combinations for people with advanced stomach or esophageal cancer that cannot be removed by surgery. Researchers will give 160 participants experimental drugs along with standard chemotherapy and immunotherapy to see if they are safe and effective.…

This study is testing whether adding new experimental drugs to standard immunotherapy and chemotherapy works better for people with advanced lung cancer that has spread. Researchers want to see if these combinations can shrink tumors more effectively and are safe for patients. Th…

This study is testing new combinations of experimental drugs for people with a type of kidney cancer that has come back after initial treatment with immunotherapy. The main goals are to see if these drug combinations are safe and if they can shrink or control the cancer. The stud…

This early-stage study is testing the safety and side effects of an experimental drug called MK-2828 in people with type 2 diabetes. Researchers will give the drug to 64 participants for about a month to see how their bodies handle it and if it affects a blood marker linked to in…

This study is testing if adding two targeted drugs, calderasib and cetuximab, to standard chemotherapy works better for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. It will involve about 477 adults who have not yet received treatment…

This large, late-stage study is testing whether an investigational drug called tulisokibart can help control moderate to severe Crohn's disease. It will involve about 1200 people whose current treatments aren't working well enough. The main goal is to see if the drug is better th…

This study is testing a new targeted drug called MK-1084 for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The main goals are to see if the drug is safe and if it can shrink or eliminate tumors. About 130 participants who hav…

This study is testing a new drug called ifinatamab deruxtecan, both by itself and combined with other treatments, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The main goals are to find a safe dose, see how well the bod…

This large, late-stage study aims to see if a new oral drug called nemtabrutinib works as well as or better than current standard drugs (ibrutinib or acalabrutinib) for people newly diagnosed with a type of blood cancer called chronic lymphocytic leukemia (CLL) or small lymphocyt…

This is a first-in-human study to test the safety and side effects of a new oral drug called MK-4716 for people with advanced solid tumors that have a specific genetic change called a KRAS alteration. The drug will be tested both by itself and in combination with other approved c…

This study is testing a new medicine called MK-3120 for people with high-risk bladder cancer that is still in the lining of the bladder and hasn't spread to the muscle. The medicine is placed directly into the bladder. The main goals are to see if the treatment is safe and if peo…

This study is testing whether a new drug called MK-2870 works better than standard chemotherapy for people with a specific type of advanced lung cancer. It is for adults whose cancer has a genetic change called EGFR and has continued to grow despite previous targeted therapy. The…

This study aims to understand the long-term safety and effectiveness of the medication tulisokibart for people with moderate to severe Crohn's disease or ulcerative colitis. It's an extension study for 1,380 participants who previously benefited from tulisokibart in earlier trial…

This study is testing whether an oral antiviral pill called molnupiravir can prevent severe illness in adults with COVID-19 who are at high risk. Over 3,000 participants will take either the study pill or a placebo to see if it reduces the need for hospitalization or medical visi…

This large Phase 3 trial is testing whether a new drug called MK-2870 (sacituzumab tirumotecan) works better than current standard treatments for women whose cervical cancer has returned or spread after their first round of chemotherapy. The study will involve about 686 participa…

This study is testing several new drug combinations for people with advanced esophageal cancer that has continued to grow despite previous standard treatment, including immunotherapy. The trial aims to find out if these new combinations are safe and can help control the cancer. I…

This study is testing whether a new drug called tulisokibart can help control symptoms in people with active rheumatoid arthritis (RA) who are already taking the standard medication methotrexate. Researchers will compare several doses of tulisokibart against a placebo (a dummy tr…

This study aims to see if a new drug called bomedemstat works better and is safer than the current standard treatment, hydroxyurea, for people with essential thrombocythemia (ET) who are starting treatment for the first time. It will involve 300 participants and will measure how …

This large Phase 3 trial is testing whether a new two-drug combination works better than current standard treatments to prevent cancer from coming back in people with triple-negative breast cancer. The study is for patients who had chemotherapy before surgery but still had some c…

This study is testing whether adding an experimental drug called zilovertamab vedotin to standard chemotherapy works better than standard chemotherapy alone for adults whose diffuse large B-cell lymphoma has come back or hasn't responded to prior treatments. The main goals are to…

This early-stage study is testing a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with a specific type of bladder cancer that hasn't spread into the muscle wall. The drug is delivered directly into the bladder. The main goals are to find a safe dose and see how wel…

This study is testing new drug combinations for people with advanced esophageal cancer that cannot be removed by surgery or has spread. Researchers are combining an existing immunotherapy drug (pembrolizumab) with a new targeted drug (I-DXd), with or without standard chemotherapy…

This large study is testing whether adding a new targeted drug called sacituzumab tirumotecan to standard chemotherapy and immunotherapy works better before surgery for certain aggressive, early-stage breast cancers. Researchers want to see if this three-drug combination helps el…

This study is testing a new drug called enlicitide decanoate to see if it is safe and effective for lowering bad cholesterol in children and teenagers with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). Researchers will measure how the drug works in…

This study is testing whether adding a new personalized cancer vaccine called V940 to the standard BCG treatment helps people with high-risk bladder cancer stay cancer-free longer. Researchers will compare the combination of V940 plus BCG against BCG treatment alone in about 308 …

This study is testing whether a new drug called bomedemstat works better than current standard treatments for people with essential thrombocythemia, a blood disorder where the body makes too many platelets. It's for patients who didn't respond well to or couldn't tolerate their p…

This study is testing if adding a new personalized cancer vaccine called V940 to standard immunotherapy and chemotherapy helps people with advanced squamous non-small cell lung cancer live longer and keeps their cancer from growing. The trial will compare results for 180 particip…

This large, late-stage study is testing a new targeted drug called ifinatamab deruxtecan against standard chemotherapy for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The main goal is to see if the new drug helps patients live long…

This study is testing whether an investigational drug called tulisokibart can reduce symptoms of ankylosing spondylitis, a type of arthritis that causes pain and stiffness in the spine and pelvis. Researchers will compare different doses of tulisokibart against a placebo in 315 p…

This study is testing the safety and effectiveness of the drug pembrolizumab in Japanese children with specific solid tumors or lymphomas, and in Japanese adults with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Researchers will measure how the body processe…

This study is testing a drug called sotatercept in children aged 1 to 18 who have pulmonary arterial hypertension (PAH), a serious condition that causes high blood pressure in the lungs. The main goal is to see if the drug is safe and how the body processes it over 24 weeks while…

This study is testing the safety and effectiveness of several different drug combinations, all built around an immunotherapy drug called pembrolizumab, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. It will enroll…

This study is testing if a new two-drug combination works better than standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The new treatment pairs a targeted drug (calderasib) with an immunotherapy (pembrol…

This study is testing whether a new targeted drug called sacituzumab tirumotecan (Sac-TMT), given alone or with another drug called bevacizumab, can help people with advanced ovarian cancer live longer without their cancer getting worse. It compares these new maintenance treatmen…

This study is testing new drug combinations for people with extensive-stage small cell lung cancer that has returned or stopped responding to prior treatment. Researchers want to see if using new immunotherapy drugs alone or together is safe and can shrink or eliminate tumors. Th…

This study is testing whether adding a personalized cancer vaccine called V940 to standard immunotherapy (pembrolizumab) after surgery helps keep lung cancer from coming back. It will enroll 680 people with non-small cell lung cancer whose tumors did not completely disappear with…

This study is testing if a new drug called opevesostat helps men with advanced prostate cancer live longer than the current standard medications (abiraterone or enzalutamide). It is for men whose cancer has spread and has worsened despite prior hormone therapy and chemotherapy. T…

This study is testing an oral drug called nemtabrutinib in people with several types of advanced blood cancers that have come back or stopped responding to other treatments. It aims to find a safe and effective dose and see how well the drug shrinks tumors and controls the diseas…

This study is for people with a certain type of lung cancer (non-small cell) that was removed by surgery but still showed some cancer cells. It tests if adding a new drug called sacituzumab tirumotecan to the standard drug pembrolizumab works better at keeping the cancer from com…

This study is testing whether adding a new experimental drug to the current standard treatment is safe and more effective for people with advanced bladder cancer. It will involve about 55 participants who have not yet received treatment for their advanced cancer. The main goals a…

This study is testing an oral medication called belzutifan for people with advanced rare tumors, including pheochromocytoma, pancreatic neuroendocrine tumors, VHL disease-associated tumors, and certain gastrointestinal cancers. The main goal is to see how well the drug shrinks tu…

This study is testing if a new two-drug combination helps people with a specific type of advanced lung cancer live longer than the current standard single-drug treatment. It will involve about 614 adults whose cancer has spread and who have not yet received treatment for it. The …

This large, late-stage study is testing if adding a new drug called MK-2870 to a standard treatment helps people with advanced squamous non-small cell lung cancer live longer. About 851 participants will first receive a standard chemotherapy and immunotherapy combination. Then, t…

This study is testing a new drug called zilovertamab vedotin in children and young adults whose cancers have come back or haven't responded to standard treatments. It will enroll about 90 participants aged 1 year and older with specific blood cancers or solid tumors. The main goa…

This study is a long-term follow-up for people who previously took part in a trial for sotatercept, a drug being tested for a complex form of pulmonary hypertension caused by a specific type of heart failure. It aims to see if the drug is safe and well-tolerated over a longer per…

This early-stage study is testing a new weight loss pill called MK-4082. Researchers want to see if it is safe and how the body processes it in healthy adults who are overweight or have obesity. The goal is to find a safe dose for future studies, as this pill could offer an alter…

This study aims to find the right dose and check the safety of an antifungal medicine called posaconazole in babies under 2 years old who have a serious fungal infection. Researchers will give the medicine to about 40 infants, first through an IV and later as a liquid by mouth, t…

This study is testing a new targeted drug called MK-1084 for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The main goals are to see if the drug is safe and if it can shrink or get rid of the cancer. The study is for people w…

This study is testing whether adding a new drug called calderasib (MK-1084) to an existing immunotherapy (pembrolizumab) works better for people with a specific type of advanced lung cancer. It will involve about 600 adults whose cancer has a KRAS G12C mutation and high levels of…

This study is testing whether a medicine called vericiguat can help children and teenagers with heart failure. Researchers will compare the drug to a placebo (an inactive substance) to see if it improves a key blood marker of heart strain and is safe for young patients. The goal …

This study is testing a new drug called patritumab deruxtecan for people with a common type of advanced breast cancer that has stopped responding to standard hormone therapies. It will compare the new drug to other treatments chosen by doctors, like chemotherapy, to see if it hel…

This study is testing a new drug called MK-2870, both by itself and combined with other cancer treatments, for people with advanced colorectal, pancreatic, or biliary tract cancers. The main goals are to see if the treatment is safe and if it helps shrink or eliminate tumors. The…

This large, late-stage trial is testing whether a new targeted drug (sacituzumab tirumotecan) combined with two existing cancer drugs works better than standard care for advanced cervical cancer that has spread. The study aims to see if this combination helps patients live longer…

This study is testing several new drug combinations for people with advanced lung cancer who haven't had any previous treatment. Researchers will give 450 participants different combinations of experimental drugs along with standard treatments to see which work best and are safes…

This study is testing an experimental drug called MK-5684, both alone and in combination with other treatments, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The main goals are to find a safe dose and see if the drug can…

This study is testing whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent lung cancer from returning after surgery. It will involve about 868 people whose stage II or III non-small cell lung cancer has been completely rem…

This study is testing whether giving new drug combinations before surgery can eliminate cancer cells in people with operable lung cancer. Researchers want to see if these treatments can completely clear cancer from tumors and lymph nodes removed during surgery. The study involves…

This study is testing an experimental drug called MK-5684 for people with advanced breast, ovarian, or endometrial cancers that have progressed after standard treatments. The drug works by blocking the body's production of hormones that can fuel these cancers. Researchers will co…

This early-stage study is testing a new drug called MK-1084 (calderasib) in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find safe doses and see how the body processes the drug, both when given alone and combined wi…

This study is testing whether a new monthly oral pill called MK-8527 works better than standard daily medication to prevent HIV infection in women. It will involve about 4,580 HIV-negative women who are at risk of getting HIV through sex. The main goals are to see if the monthly …

This study is testing whether a drug called letermovir can safely prevent cytomegalovirus (CMV) infections in children who have received kidney transplants. Researchers want to understand how the drug moves through children's bodies and what side effects it might cause. The study…

This study is testing whether a new monthly oral pill called MK-8527 works as well as or better than standard daily PrEP medication to prevent HIV infection. The trial will involve 4,390 HIV-negative adults at risk of HIV exposure. Researchers will compare how effective the month…

This study is testing if the sleep medication suvorexant can help people who are recovering from opioid addiction and also have insomnia. About 300 participants will be randomly assigned to receive either the real medication or a placebo (inactive pill) for 8 weeks. The main goal…

This study is testing whether a new drug called MK-1167, when added to standard Alzheimer's medication, can help improve memory, thinking, and daily function for people with mild to moderate Alzheimer's dementia. Researchers will compare the effects of MK-1167 against a placebo i…

This early-stage study aims to understand how a new drug called MK-2828 is processed by the body in people with impaired kidney function. Researchers will compare blood levels of the drug in 24 participants—some with kidney disease and some healthy—after they receive one or two d…

This study aims to understand how a moderate liver condition affects how the body processes a single dose of the drug nemtabrutinib. It will compare 32 participants—some with stable, moderate liver impairment and some healthy—to see how much of the drug stays in their blood and c…

This early-stage study aims to understand how a new drug, MK-2828, interacts with other common medications in the body. It involves 28 healthy participants and will measure drug levels in the blood to see if taking MK-2828 with other drugs changes how the body processes them. The…

This early-stage study aims to understand if a new investigational drug for heart failure (MK-2828) changes how the body processes two common medications: a cholesterol drug (rosuvastatin) and a water pill (furosemide). Researchers will give these drugs to 39 healthy participants…

This early-stage study aims to understand how liver impairment affects how the body processes an experimental drug called MK-1084 (calderasib). Researchers will compare drug levels and safety in 58 participants, some with stable liver disease and some who are healthy. The goal is…

This early-stage study aims to understand how a common heart medication (diltiazem) changes the way the body processes an experimental cancer drug (nemtabrutinib). Researchers will measure drug levels in the blood of 24 healthy participants who take nemtabrutinib with and without…

This study aims to see if two different auto-injector devices deliver the same amount of an investigational drug called tulisokibart into the body. Researchers will measure drug levels in the blood and check for side effects in healthy participants. The goal is to understand if t…